A review published in the Journal of Obesity & Metabolic Syndrome argues that metabolic and bariatric surgery has not been made obsolete by GLP-1 receptor agonists, and that the two should be positioned as complementary rather than competing treatments. The authors synthesize contemporary data on surgical outcomes, access disparities, and shifting perceptions of obesity treatment.

GLP-1 receptor agonists are the drug class behind the current wave of obesity pharmacotherapy, working through a gut hormone pathway that affects appetite and glucose regulation. Metabolic and bariatric surgery, abbreviated MBS in the paper, covers the surgical procedures used for severe obesity.

The scale of the problem

The review puts the global burden at nearly one billion adults affected by obesity, with substantially increased risk of cardiometabolic disease, malignancy and premature mortality. That framing matters because it sets up the authors' central complaint, which is not about drugs at all.

Surgery reaches under 1% of eligible patients

Despite what the authors describe as dramatic improvements in safety, efficacy and long-term outcomes, MBS reaches fewer than 1% of eligible patients. The barriers they name are limited patient and provider awareness, misconceptions about surgical risk, and significant disparities in access to care.

That is the most striking figure in the paper, and it reframes the whole GLP-1 debate. A treatment used by under one in a hundred eligible people was never going to be displaced by a newer option: it was already barely being used.

Key results

On the head-to-head question, the review states that emerging evidence shows MBS produces greater and more durable weight loss than GLP-1 receptor agonists alone. The authors immediately add that this does not make the therapies competitive.

Instead they describe two integrated roles: GLP-1 drugs as neoadjuvant treatment to optimize surgical candidacy, and as adjunctive treatment for inadequate weight loss or postoperative weight regain. From that, they propose a chronic weight management model combining pharmacotherapy, surgery and multidisciplinary care along a continuous treatment spectrum.

Limitations

This is a narrative review rather than a trial, so it reports no new outcome data and sets no formal evidence-grading criteria. The proposed care model is presented as a proposal, and the authors say positioning the two modalities as complementary "may" improve long-term outcomes, expand access and better address obesity's chronic nature.

Bottom line

The authors' answer to their own headline question is no: the scalpel is not obsolete, and durability still favors surgery. What remains unsettled is whether an integrated pharmacotherapy-plus-surgery pathway actually improves long-term outcomes in practice, which this review proposes rather than demonstrates.